- Fellowship - University of Iowa Hospitals and Clinics (1999-2002), Cardiology
- Residency - New York Hospital Medical Center of Queens (1996-1999), Internal Medicine
- Medical School - Minsk Medical Institute (1986-1992)
- Fellowship - University of Iowa Hospitals and Clinics (2002-2003), Interventional Cardiology
Subhash Banerjee, M.D.
- Internal Medicine - Cardiology
- General Cardiology
Subhash Banerjee, M.D., is a Professor in the UT Southwestern Department of Internal Medicine. He also serves as the Chief of Cardiology and Director of the Cardiac Catheterization Laboratory at the VA North Texas Health Care System in Dallas.
Dr. Banerjee earned his medical degree at Minsk Medical Institute and performed residencies in internal medicine at SJH/Batra Hospitals and New York Presbyterian Hospital. He then completed fellowships in cardiovascular diseases and interventional cardiology at the University of Iowa Hospitals and Clinics. He joined the UT Southwestern faculty in 2004.
Dr. Banerjee is the Director of the Cardiovascular Innovations annual scientific meeting, a section editor for the American College of Cardiology (ACC) Interventional Board Review, and a grant reviewer for the National Institutes of Health. He is also part of the VA Health Care System’s National Field Advisory Board for Cardiology, National Transcatheter Valve Therapy Committee, and Cath Lab Quality/Performance Improvement (CART-CL) Publication and Grants Committee.
Dr. Banerjee is a member of the American Heart Association, American College of Cardiology, and Society for Cardiovascular Angiography and Interventions. He is also a member of the UT Southwestern Cardiology Executive Council, the organizing committee of the ACC and Transcatheter Cardiovascular Therapeutics, the American Board of Internal Medicine interventional cardiology question-writing committee, and the ACC Peripheral Vascular Disease Council.
He is an editorial board member for leading medical journals, including the American Journal of Cardiology and the Journal of Endovascular Therapy. He is also a reviewer for several journals, including the Journal of the American College of Cardiology and Circulation.
Dr. Banerjee has been the recipient of grants from the American Heart Association, National Institutes of Health, and VA Cooperative Clinical Trial, as well as major industry grants. He is the principal investigator and founder of the Excellence in Peripheral Artery Disease (XLPAD) multicenter registry, and he holds medical device patents for a mobile health platform and a cardiovascular trapping sheath.
Dr. Banerjee was included in D Magazine's Best Doctors list for 2018.
Meet Dr. Banerjee
Interventional Cardiologist in Dallas
Interventional cardiologist and endovascular specialist Subhash Banerjee, M.D., has a passion for helping his patients by leveraging the most advanced, forward-thinking research and treatments available.
An internationally recognized expert in his field, Dr. Banerjee is highly specialized in complex cardiovascular procedures that combat the growing epidemic of heart and vascular disease.
He has dedicated his career to minimally invasive coronary artery, peripheral artery, and transcatheter aortic valve replacement procedures (TAVR). TAVR is a breakthrough new treatment option for many patients who wouldn’t be candidates for traditional open surgery.
Dr. Banerjee is also a leading expert in high-risk percutaneous coronary interventions with hemodynamic support devices, or heart pumps, as well as percutaneous treatment of coronary and peripheral artery chronic total occlusions.
“Everyone has a strength,” he says. “These procedures require in-depth and precise knowledge of multitudes of devices and technologies. And my strength is that I have been completely dedicated to these complex procedures for the past 15 years. I didn’t want to dilute myself by doing multiple things. So I do these procedures every day.”
That singular focus allows Dr. Banerjee to provide the highest standard of care to his cardiology patients, some of whom undergo extensive, multi-hour procedures in order to regain full heart function. He also makes sure to stay abreast of the latest developments in heart care. His dedication to leading-edge treatments is the reason he is so heavily involved in research.
A Lifelong Love of Research
In his decades of research, Dr. Banerjee has led many landmark medical research trials and has published more than 300 peer-reviewed manuscripts and book chapters.
It’s his love for research that helped draw him to the field of interventional cardiology. Dr. Banerjee studied internal medicine and cardiovascular diseases prior to starting his career as a basic scientist. When he was awarded a prestigious grant from the American Heart Association in 2000, he had the chance to research adult stem cells and their role in repairing heart and blood vessels.
“While getting involved in vascular biology, I developed a keen interest in how I could actually use the research to change the course of disease,” he says. “That’s what drew me to minimally invasive endovascular procedures. The research inspired me to want to actually affect those changes in real human patients.”
The American Heart Association research led him to a fellowship in interventional cardiology, which became his life’s work.
“My whole focus has been to be one of the few people who is immersed so deeply in these complex procedures that when any new technology or new treatment comes along, we can quickly start learning it and bring those new technologies to our institution,” he says.
As heart and vascular disease become increasingly common, more research is being conducted into these conditions than ever before. And the progress is significant.
“The past five years are the first five years where we have seen a decline in death rates from heart and vascular disease,” Dr. Banerjee says.
That is due in large part to new research being put into practice that improves patient outcomes, shortens recovery time, and advances management of risk factors.
“For example, the first generation of biodegradable stents is being issued and approved by the FDA. Because most stents are made out of metal, they are there for the entire life of the patient,” Dr. Banerjee says. “But biodegradable stents completely disappear after six or eight months, and the blood vessel assumes its normal function.”
A strategy buff who grew up playing chess and who even considered becoming a professional player, Dr. Banerjee still enjoys the challenge of solving a complex problem in both his work and personal life. One of his favorite ways to challenge himself is to learn a new language. Aside from English, he has learned Hindi, Bengali, and Russian.
- American College of Cardiology, Member
- American Heart Association, Member
- Society of Coronary Angiography and Interventions, Member
- Excellence in Research Mentoring 2013, University of Texas Southwestern Medical Center, Internal Medicine Residency Program
- Leadership Award in Interventional Cardiology 2010, Cardiovascular Research Technologies
- Emerging Cardiology Faculty Recognition 2010, American College of Cardiology
- Young Leadership Award in Cardiology 2010, Cardiovascular Revascularization Therapy
- Emerging Cardiology Faculty Nomination 2007, American College of Cardiology
- Teacher of the Year 1996, New York Hospital Queens Cornell College of Medicine
- John Dwoek Teacher of the Year Award 1999, New York Hospital Medical Center Queens Cornell University NY
- Post-doctoral Fellowship Award 2000, American Heart Association
- Researcher of the Year 2013, VA North Texas Health Care System
- M.D., Summa cum laude, Minsk Medical Institute
Multi-Ligand Poly(L-Lactic-co-Glycolic Acid) Nanoparticles Inhibit Activation of Endothelial Cells.
Xu H, Kona S, Su LC, Tsai YT, Dong JF, Brilakis ES, Tang L, Banerjee S, Nguyen KT Journal of cardiovascular translational research 2013 May
Low-Density Lipoprotein Cholesterol: How Low Can We Go?
Sherbet DP, Garg P, Brilakis ES, Banerjee S American journal of cardiovascular drugs : drugs, devices, and other interventions 2013 Apr
Embolic capture angioplasty in peripheral artery interventions.
Hadidi OF, Mohammad A, Zankar A, Brilakis ES, Banerjee S Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 2012 Oct 19 5 611-6
Enhanced endothelialization of a new stent polymer through surface enhancement and incorporation of growth factor-delivering microparticles.
Xu H, Nguyen KT, Brilakis ES, Yang J, Fuh E, Banerjee S Journal of cardiovascular translational research 2012 Aug 5 4 519-27
Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention.
Banerjee S, Weideman RA, Weideman MW, Little BB, Kelly KC, Gunter JT, Tortorice KL, Shank M, Cryer B, Reilly RF, Rao SV, Kastrati A, de Lemos JA, Brilakis ES, Bhatt DL The American journal of cardiology 2011 Mar 107 6 871-8
Pilot Trial of Cryoplasty or Conventional Balloon Post-Dilation of Nitinol Stents for Revascularization of Peripheral Arterial Segments: The COBRA Trial.
Banerjee S, Das TS, Abu-Fadel MS, Dippel EJ, Shammas NW, Tran DL, Zankar A, Varghese C, Kelly KC, Weideman RA, Little BB, Reilly RF, Addo T, Brilakis ES Journal of the American College of Cardiology 2012 Oct 60 15 1352-9
A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial.
Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S Journal of the American College of Cardiology 2009 Mar 53 11 919-28
Influence of chronic total occlusions on coronary artery bypass graft surgical outcomes.
Banerjee S, Master RG, Peltz M, Willis B, Mohammed A, Little BB, DiMaio MJ, Jessen ME, Brilakis ES Journal of cardiac surgery 2012 Nov 27 6 662-7
Medical management after coronary stent implantation: a review.
Brilakis ES, Patel VG, Banerjee S JAMA : the journal of the American Medical Association 2013 Jul 310 2 189-98
Endothelial progenitor cell response to antiproliferative drug exposure.
Banerjee S, Xu H, Fuh E, Nguyen KT, Garcia JA, Brilakis ES, Bhatt DL Atherosclerosis 2012 Nov 225 1 91-8
- Multi-Ligand Poly(L-Lactic-co-Glycolic Acid) Nanoparticles Inhibit Activation of Endothelial Cells.
- Anti-platelet and anti-thrombotic therapies
- Complex coronary and peripheral vascular interventions (special emphasis: chronic total occlusion)
- Endothelial progenitor stem cell research in cardiovascular medicine
- General Cardiology